Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lexicon Pharmaceuticals
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of ulcerative colitis of at least 6 months duration
Disease extends at least 15 cm proximally from the anal verge, documented within the past 3 years
Flare occurs on 5-aminosalicylic acid (5-ASA)/mesalamine therapy and subject is willing to remain on a stable dose for the duration of the study
Age ≥18 and \<70 years of age
Able and willing to provide written informed consent
You may not be if
Prior terminal ileum or colonic surgery, except appendectomy or hemorrhoid surgery
Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease
Clinical signs of fulminant colitis or toxic megacolon
History of dysplasia associated lesion or mass (DALM)
Subjects who have had surgery for ulcerative colitis, or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study
History of primary sclerosing cholangitis
Any physical or laboratory abnormality deemed by the investigator as clinically significant
Major surgery within 60 days of Screening
Use of any investigational agent within 30 days of Screening or any therapeutic protein or antibody within 90 days of Screening
Clareo Health | A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
